Naloxone potentiates the inotropic effects of isoproterenol in vitro by a nonopiate receptor mechanism.
Naloxone potentiates the effects of adrenergic agonists when administered to hypovolemic dogs, and it has been assumed that this effect is due to naloxone's action at opiate receptors. To help determine the site and mechanism of this interaction, we administered naloxone and its "d" stereo-isomer (which does not bind to opiate receptors) to guinea pig papillary muscles in the presence and absence of pharmacologic (isoproterenol) and physiologic (treppe) inotropic stimulation. In control muscles and in rapidly paced muscles, naloxone was without significant inotropic effect. In the presence of isoproterenol, d- and l-naloxone exerted significant positive inotropic effects that were dose dependent. We conclude that, since both d- and l-naloxone potentiated the inotropic effects of isoproterenol and this was seen in the absence of opioids, naloxone may increase contractility by a nonopiate receptor-mediated mechanism.
Lechner
R B
RB
Department of Anesthesiology, University of Virginia, Charlottesville 22908.
D000818:Animals; D002118:Calcium / Q000378:metabolism; D015220:Calcium Channels / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology*; D009200:Myocardial Contraction / Q000187:drug effects*; D009270:Naloxone / Q000494:pharmacology*; D015221:Potassium Channels / Q000187:drug effects; D011957:Receptors, Opioid / Q000187:drug effects*; D013237:Stereoisomerism; D013268:Stimulation, Chemical
D015220:Calcium Channels; D015221:Potassium Channels; D011957:Receptors, Opioid; D009270:Naloxone; D007545:Isoproterenol; D002118:Calcium